Requip medication  for Parkinson's disease and Restless Legs Syndrome by Ray Sahelian, M.D.

Requip (ropinirole hydrochloride) is an orally administered non-ergoline dopamine agonist.

Requip for Parkinson's disease

Requip is prescribed for the treatment of Parkinson’s disease.

Requip for restless legs syndrome

Requip is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Requip Ropinirole prolonged release: in advanced Parkinson's disease.
Requip Ropinirole prolonged release is a dopamine receptor agonist that is indicated for the treatment of Parkinson's disease. Once-daily Requip prolonged release and three-times-daily immediate release have similar exposure over 24 hours. The prolonged-release formulation is associated with fewer fluctuations in plasma Requip concentrations. Requip prolonged release 6-12 mg once daily is generally well tolerated in patients with advanced Parkinson's disease; adverse events are generally typical of non-ergoline dopamine receptor agonists.